Return to Publications
May 2018
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.
tanning

Indoor Tanners: Are they taking Steps to Protect against Skin Cancer?

Research has shown that indoor tanners are at a higher risk of developing melanoma and other skin cancers. With that, it is recommended they be screened for skin cancer at regular intervals - but are they getting themselves checked and taking other preventative measures? Rutgers Cancer Institute of New Jersey researcher Carolyn J. Heckman, PhD, who is also an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, explored this topic with colleagues at Fox Chase Cancer Center. The work appears in the April 4 edition of JAMA Dermatology.

Peter Cole, MD

Embrace Kids Foundation Chair in Pediatric Hematology/Oncology Proposed at Rutgers Cancer Institute

With an aim to propel precision medicine and other cutting-edge research to better inform treatment decisions for the youngest of patients, nationally distinguished pediatric hematology/oncology leader Peter D. Cole, MD, has been named the Chief of Pediatric Hematology/Oncology at Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School and the proposed Embrace Kids Foundation Chair in Pediatric Hematology/Oncology, which was officially established at last month's Rutgers Board of Governors meeting.

X.F. Steven Zheng, PhD

Identifying a New Therapeutic Target for the Most Common Type of Lung Cancer

Research by Rutgers Cancer Institute of New Jersey investigators has identified novel functions of the superoxide dismutase 1 (SOD1) enzyme providing support that it could serve as a therapeutic target in the most common type of lung cancer. Results of the work, generated by the laboratory of X.F. Steven Zheng, PhD, co-director of the Cancer Pharmacology Program at Rutgers Cancer Institute, were presented at the recent American Association for Cancer Research Annual Meeting.

Andrew M. Evens, DO, MSc, FACP

A Closer Look at the Association between Breast Implants and an Uncommon Form of Cancer

For the past seven years, the U.S. Food and Drug Administration has reported on cases of a type of lymphoma associated with breast implants. In April, the FDA noted a rise in the amount of these cases over the past year - 414 cases - up from 359 in the previous year. Andrew M. Evens, DO, MSc, FACP, director of the Lymphoma Program and associate director for clinical services at Rutgers Cancer Institute of New Jersey, and medical director of the oncology service line at RWJBarnabas Health, shares some insight.

DNA

CHIPing away at Cancer Tumors through Genomic Analysis

Rutgers Cancer Institute of New Jersey precision medicine researchers, in collaboration with investigators at Foundation Medicine, Inc., have discovered that some mutations detected in comprehensive, clinical genome sequencing of patients with solid tumors do not originate from cancer cells, but arise from mutated hematopoietic cells that infiltrate the tumor microenvironment. The findings, they say, have direct implications for cancer patients, specifically in accurately interpreting their molecular testing results. The work appeared in the April 20 edition of Blood.